β-glucans and their applications in cancer therapy: Focus on human studies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 5, 2013, Pages 709-719

  Aleem, Eiman ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Alexandria University Faculty Of Science   (Egypt)

Author keywords

glucans; Clinical trials; Human cancer; Lentinan; Maitake; Schizophyllan

Indexed keywords

AROMATASE; ASCORBIC ACID; BETA GLUCAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; FUNGAL EXTRACT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; KRESTIN; LENTINAN; MAITAKE EXTRACT; PACLITAXEL; PROTEOGLYCAN; SCHIZOPHYLLAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE; CELL PROLIFERATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GRIFOLA FRONDOSA; HUMAN; JOINT SWELLING; MULTIPLE CYCLE TREATMENT; NAUSEA; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW;

AGARICALES; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BETA-GLUCANS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PLANT EXTRACTS;

EID: 84880148501     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313050005     Document Type: Review

References (118)

1. Mantovani, M.S.; Bellini, M.F.; Angeli, J.P.; Oliveira, R.J.; Silva, A.F.; Ribeiro, L.R. Beta-Glucans in promoting health: Prevention against mutation and cancer. Mutat. Res., 2008, 658(3), 154-161.
2. Chen, J.; Seviour, R. Medicinal importance of fungal beta-(1-->3), (1-->6)-glucans. Mycol. Res., 2007, 111(Pt 6), 635-652.
3. Lindequist, U.; Niedermeyer, T.H.; Julich, W.D. The pharmacological potential of mushrooms. Evid. Based Complement Alternat. Med., 2005, 2(3), 285-299.
4. Chen, J.; Huang, X.F. The effects of diets enriched in beta-glucans on blood lipoprotein concentrations. J. Clin. Lipidol., 2009, 3(3), 154-158.
5. Chen, J.; Raymond, K. Beta-glucans in the treatment of diabetes and associated cardiovascular risks. Vasc. Health Risk Manag., 2008, 4(6), 1265-1272.
6. Novaes, M.R., Novaes, L.C., Taveira, V.C. Natural products from Agaricales Medicinal Mushrooms: Biology, Nutritional Properties, and pharmacological effects on cancer. Revista Brasileira de Cancerologia 2007, 53(4), 411-420.
7. Chan, G.C.; Chan, W.K.; Sze, D.M. The effects of beta-glucan on human immune and cancer cells. J. Hematol. Oncol., 2009, 2, 25.
8. Sze, D.M.; Chan, G.C. Supplements for immune enhancement in hematologic malignancies. Hematology Am. Soc. Hematology Hematol. Educ. Program, 2009, 313-319.
9. Murphy, E.A.; Davis, J.M.; Carmichael, M.D. Immune modulating effects of beta-glucan. Curr. Opin. Clin. Nutr. Metab. Care, 2010, 13(6), 656-661.
10. Driscoll, M.; Hansen, R.; Ding, C.; Cramer, D.E.; Yan, J. Therapeutic potential of various beta-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biol. Ther., 2009, 8, (3)218-225.
11. Bohn, J.A.; BeMiller, J.N. (1->3)-beta-D-glucans as biological response modifiers: A review of structure-functional activity relationships. Carbohyd. Polym., 1995, 28, (1)3-14.
12. Sullivan, R.; Smith, J.E.; Rowan, N.J. Medicinal mushrooms and cancer therapy-translating a traditional practice into Western medicine. Perspect. Biol. Med., 2006, 49(2), 159-170.
13. Borchers, A.T.; Stern, J.S.; Hackman, R.M.; Keen, C.L.; Gershwin, M.E. Mushrooms, tumors, and immunity. Proc. Soc. Exp. Biol. Med., 1999, 221(4), 281-293.
14. Smith, J.W., Rowan, N.J., Sullivan, R. Medicinal mushrooms: A rapidly developing area of biotechnology for cancer therapy and other bioactivities. Biotechnol. Lett., 2002, 24, 1839-1845.
15. Daba, A.S., Kabeil, S.S., Botros, W.A., El-Saadani, M.A. Production of Mushroom (Pleurotus ostreatus) in Egypt as a Source of Nutritional and Medicinal Food. World J. Agric. Sci., 2008, 4(5), 630-634.
16. Lucas, E.H. Tumor inhibitors in Boletus edulis and other Holobasidiomycetes. Antibiot. Chemother., 1957, 7, 1-4.
17. Martin, D.S.; Hayworth, P.; Fugmann, R.A.; English, R.; McNeill, H.W. Combination Therapy with Cyclophosphamide and Zymosan on a Spontaneous Mammary Cancer in Mice. Cancer Res., 1964, 24, 652-654.
18. Lee, S.A.; Kang, D.; Nishio, H.; Lee, M.J.; Kim, D.H.; Han, W.; Yoo, K.Y.; Ahn, S.H.; Choe, K.J.; Hirvonen, A.; Noh, D.Y. Methylenetetrahydrofolate reductase polymorphism, diet, and breast cancer in Korean women. Exp. Mol. Med., 2004, 36(2), 116-121.
19. Hong, S.A.; Kim, K.; Nam, S.J.; Kong, G.; Kim, M.K. A casecontrol study on the dietary intake of mushrooms and breast cancer risk among Korean women. Int. J. Cancer, 2008, 122(4), 919-923.
20. Zhang, M.; Huang, J.; Xie, X.; Holman, C.D. Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women. Int. J. Cancer, 2009, 124(6), 1404-1408.
21. Shin, A.; Kim, J.; Lim, S.Y.; Kim, G.; Sung, M.K.; Lee, E.S.; Ro, J. Dietary mushroom intake and the risk of breast cancer based on hormone receptor status. Nutr. Cancer, 2010, 62(4), 476-483.
22. Kim, H.J.; Chang, W.K.; Kim, M.K.; Lee, S.S.; Choi, B.Y. Dietary factors and gastric cancer in Korea: A case-control study. Int J Cancer. 2002, 97(4), 531-535.
23. Hara, M.; Hanaoka, T.; Kobayashi, M.; Otani, T.; Adachi, H.Y.; Montani, A.; Natsukawa, S.; Shaura, K.; Koizumi, Y.; Kasuga, Y.; Matsuzawa, T.; Ikekawa, T.; Sasaki, S.; Tsugane, S. Cruciferous vegetables, mushrooms, and gastrointestinal cancer risks in a multicenter, hospital-based case-control study in Japan. Nutr. Cancer, 2003, 46(2), 138-147.
24. Hobbs, C. Medicinal mushrooms: an exploration of tradition, healing and culture. Santa Cruz, CA: Botanica Press, 1995.
25. Wasser, S.P. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl. Microbiol. Biotechnol., 2002, 60(3), 258-274.
26. Ahn, W.S.; Kim, D.J.; Chae, G.T.; Lee, J.M.; Bae, S.M.; Sin, J.I.; Kim, Y.W.; Namkoong, S.E.; Lee, I.P. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int. J. Gynecol. Cancer, 2004, 14(4), 589-594.
27. Novaes, M.R.C.G., Novaes, L.C.G. Drug-nutrient in edible mushrooms and other basidomycetous Agaricales. Revista brasileira de nutrição clínica, 2005, 20, 181-187.
28. Fortes, R.C., Novaes, M.R.C.G. The effects of Agaricus sylvaticus fungi dietary supplementation on the metabolism and blood pressure of patients with colorectal cancer during post surgical phase. Nutr. Hosp., 2011, 26, 176-186.
29. Novaes, M.R.; Valadares, F.; Reis, M.C.; Goncalves, D.R.; Menezes Mda, C. The effects of dietary supplementation with Agaricales mushrooms and other medicinal fungi on breast cancer: Evidence-based medicine. Clinics (Sao Paulo), 2011, 66(12), 2133-2139.
30. Ooi, V.E.; Liu, F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr. Med. Chem., 2000, 7(7), 715-729.
31. Yoshino, S.; Watanabe, S.; Imano, M.; Suga, T.; Nakazawa, S.; Hazama, S.; Oka, M. Improvement of QOL and prognosis by treatment of superfine dispersed lentinan in patients with advanced gastric cancer. Hepato-Gastroenterol., 2010, 57(97), 172-177.
32. Oba, K.; Kobayashi, M.; Matsui, T.; Kodera, Y.; Sakamoto, J. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Res., 2009, 29(7), 2739-2745.
33. Kataoka, H.; Shimura, T.; Mizoshita, T.; Kubota, E.; Mori, Y.; Mizushima, T.; Wada, T.; Ogasawara, N.; Tanida, S.; Sasaki, M.; Togawa, S.; Sano, H.; Hirata, Y.; Ikai, M.; Mochizuki, H.; Seno, K.; Itoh, S.; Kawai, T.; Joh, T. Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life. Hepato-gastroenterol., 2009, 56(90), 547-550.
34. Nimura, H.; Mitsumori, N.; Takahashi, N.; Kashimura, H.; Takayama, S.; Kashiwagi, H.; Yanaga, K. [S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]. Gan to kagaku ryoho. Cancer & Chemotherapy, 2006, 33 Suppl 1, 106-109.
35. Nimura, H.; Mitsumori, N.; Tsukagoshi, S.; Nakajima, M.; Atomi, Y.; Suzuki, S.; Kusano, M.; Yoshiyuki, T.; Tokunaga, A. [Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer]. Gan to kagaku ryoho. Cancer & Chemotherapy, 2003, 30(9), 1289-1296.
36. Nakano, H.; Namatame, K.; Nemoto, H.; Motohashi, H.; Nishiyama, K.; Kumada, K. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: Effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. Hepato-gastroenterol, 1999, 46(28), 2662-2668.
37. Higashi, D.; Seki, K.; Ishibashi, Y.; Egawa, Y.; Koga, M.; Sasaki, T.; Hirano, K.; Mikami, K.; Futami, K.; Maekawa, T.; Sudo, M. The effect of lentinan combination therapy for unresectable advanced gastric cancer. Anticancer Res., 2012, 32(6), 2365-2368.
38. Hazama, S.; Watanabe, S.; Ohashi, M.; Yagi, M.; Suzuki, M.; Matsuda, K.; Yamamoto, T.; Suga, Y.; Suga, T.; Nakazawa, S.; Oka, M. Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer. Anticancer Res., 2009, 29(7), 2611-2617.
39. Wang, J.L.; Bi, Z.; Zou, J.W.; Gu, X.M. Combination therapy with lentinan improves outcomes in patients with esophageal carcinoma. Mol. Med. Report, 2012, 5(3), 745-748.
40. Isoda, N.; Eguchi, Y.; Nukaya, H.; Hosho, K.; Suga, Y.; Suga, T.; Nakazawa, S.; Sugano, K. Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma. Hepato-gastroenterol., 2009, 56(90), 437-441.
41. Yang, P.; Liang, M.; Zhang, Y.; Shen, B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv. Ther., 2008, 25(8), 787-794.
42. Shimizu, K.; Watanabe, S.; Matsuda, K.; Suga, T.; Nakazawa, S.; Shiratori, K. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer. Hepato-gastroenterol., 2009, 56(89), 240-244.
43. Wang, C.; Hou, Y. Determination of trace elements in three mushroom samples of basidiomycetes from Shandong, China. Biol. Trace Elem. Res., 2011, 142(3), 843-847.
44. Yeh, J.Y.; Hsieh, L.H.; Wu, K.T.; Tsai, C.F. Antioxidant properties and antioxidant compounds of various extracts from the edible basidiomycete Grifola frondosa (Maitake). Molecules, 2011, 16(4), 3197-3211.
45. Yang, B.K.; Gu, Y.A.; Jeong, Y.T.; Jeong, H.; Song, C.H. Chemical characteristics and immuno-modulating activities of exobiopolymers produced by Grifola frondosa during submerged fermentation process. Int. J. Biol. Macromol., 2007, 41(3), 227-233.
46. Wu, M.J.; Cheng, T.L.; Cheng, S.Y.; Lian, T.W.; Wang, L.; Chiou, S.Y. Immunomodulatory properties of Grifola frondosa in submerged culture. J. Agric. Food Chem., 2006, 54(8), 2906-2914.
47. Jeurink, P.V.; Noguera, C.L.; Savelkoul, H.F.; Wichers, H.J. Immunomodulatory capacity of fungal proteins on the cytokine production of human peripheral blood mononuclear cells. Int. Immunopharmacol., 2008, 8(8), 1124-1133.
48. Mayell, M. Maitake extracts and their therapeutic potential. Altern. Med. Rev., 2001, 6(1), 48-60.
49. Nanba, H.; Kubo, K. Antitumor substance extracted from Grifola. 1998.
50. Kodama, N.; Komuta, K.; Nanba, H. Can maitake MD-fraction aid cancer patients? Alt. Med. Rev., 2002, 7(3), 236-239.
51. Kodama, N.; Komuta, K.; Nanba, H. Effect of Maitake (Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients. J. Med. Food, 2003, 6(4), 371-377.
52. Kodama, N.; Komuta, K.; Sakai, N.; Nanba, H. Effects of DFraction, a polysaccharide from Grifola frondosa on tumor growth involve activation of NK cells. Biol. Pharm. Bull., 2002, 25(12), 1647-1650.
53. Deng, G.; Lin, H.; Seidman, A.; Fornier, M.; D'Andrea, G.; Wesa, K.; Yeung, S.; Cunningham-Rundles, S.; Vickers, A.J.; Cassileth, B. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: Immunological effects. J. Cancer Res. Clin. Oncol., 2009, 135(9), 1215-1221.
54. Rajamahanty, S.; Louie, B.; O'Neill, C.; Choudhury, M.; Konno, S. Possible disease remission in patient with invasive bladder cancer with D-fraction regimen. Int. J. Gen. Med., 2009, 2, 15-17.
55. Jones, K. Maitake: A potent medicinal food. Alt. Comp. Ther., 1998, 4, 420-429.
56. Nanba, H. Results of non-controlled clinical study for various cancer patients using Maitake D-fraction. Explore, 1995, 6, 19-21.
57. Black, W. Several apparent errors surfaced on reading the article in the June 2002 issue of Alternative Medicine Review by Kodama et al. entitled "Can maitake MD-fraction aid cancer patients"? Alt. Med. Rev., 2002, 7(6), 451; author reply 452-454.
58. Nanba, H.; Kubo, K. Effect of Maitake D-fraction on cancer prevention. Ann. N Y Acad. Sci., 1997, 833, 204-207.
59. Konno, S. Synergistic potentiation of D-fraction with vitamin C as possible alternative approach for cancer therapy. Int. J. Gen. Med., 2009, 2, 91-108.
60. Nanba, H. Maitake D-fraction: Healing and preventive potential for cancer. J. Orthomol. Med., 1997, 12, 43-49.
61. Fortes, C.R.; Recôva, L.V.; Lima, M.; Novaes M.R.C.G. Life quality of postsurgical patients with colorectal cancer after supplemented diet with agaricus sylvaticus fungus. Nutr. Hosp., 2010, 25(4), 586-596.
62. Gennari, J.L.; Veronesi, R.; Gennari, M.S. Edible mushroom Agaricus sylvaticus used as therapeutics complement in a patient with breast cancer and lung metastasis. Rev. Bras. Med., 2002, 59, 537-538.
63. Lima, C.U.; Souza, V.C.; Morita, M.C.; Chiarello, M.D.; Karnikowski, M.G. Agaricus blazei Murrill and inflammatory mediators in elderly women: A randomized clinical trial. Scandinavian J. Immunol., 2012, 75(3), 336-341.
64. Kidd, P.M. The use of mushroom glucans and proteoglycans in cancer treatment. Altern. Med. Rev., 2000, 5(1), 4-27.
65. Sun, C.; Rosendahl, A.H.; Wang, X.D.; Wu, D.Q.; Andersson, R. Polysaccharide-K (PSK) in cancer--old story, new possibilities? Curr. Med. Chem., 2012, 19(5), 757-762.
66. Fujimoto, S.; Orita, K.; Kimura, T.; Kondo, T.; Taguchi, T.; Yoshida, K.; Ogawa, N.; Furue, H. [Clinical evaluation of SPG (schizophyllan) as a therapeutic adjuvant after surgery of gastric cancer-controlled study by an envelope method]. Gan to kagaku ryoho. Cancer & Chemotherapy, 1983, 10(4 Pt 2), 1135-1145.
67. Fujimoto, S.; Furue, H.; Kimura, T.; Kondo, T.; Orita, K.; Taguchi, T.; Yoshida, K.; Ogawa, N. Clinical evaluation of schizophyllan adjuvant immunochemotherapy for patients with resectable gastric cancer--a randomized controlled trial. Jpn. J. Surg., 1984, 14(4), 286-292.
68. Fujimoto, S.; Furue, H.; Kimura, T.; Kondo, T.; Orita, K.; Taguchi, T.; Yoshida, K.; Ogawa, N. Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: A randomised controlled study. Eur. J. Cancer, 1991, 27(9), 1114-1118.
69. Nakao, I.; Uchino, H.; Orita, K.; Kaido, I.; Kimura, T.; Goto, Y.; Kondo, T.; Takino, T.; Taguchi, T.; Nakajima, T.; Fujimoto, S.; Miyazaki, T.; Miyoshi, A.; Yachi, A.; Yoshida, K.; Ogawa, N.; Furue, H. [Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer--a randomized comparative study by an envelope method]. Gan to kagaku ryoho. Cancer & Chemotherapy, 1983, 10(4 Pt 2), 1146-1159.
70. Furue, H.; Uchino, H.; Orita, K.; Kimura, T.; Goto, Y.; Kondo, T.; Sato, S.; Takino, T.; Taguchi, T.; Nakao, I. [Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer (the second report)--a randomized controlled study]. Gan to kagaku ryoho. Cancer & Chemotherapy, 1985, 12(6), 1272-1277.
71. Okamura, K.; Suzuki, M.; Chihara, T.; Fujiwara, A.; Fukuda, T.; Goto, S.; Ichinohe, K.; Jimi, S.; Kasamatsu, T.; Kawai, N.; et al. Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer. A randomized controlled study. Cancer, 1986, 58(4), 865-872.
72. Okamura, K.; Yajima, A.; Noda, K. Adjuvant immunotherapy for cervical cancer. Two randomized controlled studies using OK-432 or sizofiran. J. Chemother., 1989, 1(4 Suppl), 1222-1224.
73. Okamura, K.; Suzuki, M.; Chihara, T.; Fujiwara, A.; Fukuda, T.; Goto, S.; Ichinohe, K.; Jimi, S.; Kasamatsu, T.; Kawai, N. Clinical evaluation of sizofiran combined with irradiation in patients with cervical cancer. A randomized controlled study; a five-year survival rate. Biotherapy., 1989, 1(2), 103-107.
74. Okamura, K.; Hamazaki, Y.; Yajima, A.; Noda, K. Adjuvant immunotherapy: Two randomized controlled studies of patients with cervical cancer. Biomedicine & Pharmacotherapy, 1989, 43(3), 177-181.
75. Noda, K.; Takeuchi, S.; Yajima, A.; Akiya, K.; Kasamatsu, T.; Tomoda, Y.; Ozawa, M.; Sekiba, K.; Sugimori, H.; Hashimoto, S. Clinical effect of sizofiran combined with irradiation in cervical cancer patients: A randomized controlled study. Cooperative Study Group on SPG for Gynecological Cancer. Jpn. J. Clin. Oncol., 1992, 22(1), 17-25.
76. Miyazaki, K.; Mizutani, H.; Katabuchi, H.; Fukuma, K.; Fujisaki, S.; Okamura, H. Activated (HLA-DR+) T-lymphocyte subsets in cervical carcinoma and effects of radiotherapy and immunotherapy with sizofiran on cell-mediated immunity and survival. Gynecologic. Oncol., 1995, 56(3), 412-420.
77. Nakano, T.; Oka, K.; Hanba, K.; Morita, S. Intratumoral administration of sizofiran activates Langerhans cell and T-cell infiltration in cervical cancer. Clin. Immunol. Immunopathol., 1996, 79(1), 79-86.
78. Inoue, M.; Tanaka, Y.; Sugita, N.; Yamasaki, M.; Yamanaka, T.; Minagawa, J.; Nakamuro, K.; Tani, T.; Okudaira, Y.; Karita, T. Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: A prospective randomized controlled study. Biotherapy, 1993, 6(1), 13-18.
79. Chen, J.T.; Hasumi, K.; Masubuchi, K. Interferon-alpha, interferon-gamma and sizofiran in the adjuvant therapy in ovarian cancer--a preliminary trial. Biotherapy, 1992, 5(4), 275-280.
80. Kano, Y.; Kakuta, H.; Hashimoto, J. Effect of sizofiran on regional lymph nodes in patients with head and neck cancer. Biotherapy, 1996, 9(4), 257-262.
81. Kimura, Y.; Tojima, H.; Fukase, S.; Takeda, K. Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta oto-laryngologica. Supplementum, 1994, 511, 192-195.
82. Hatae, M.; Noda, K.; Yajima, A.; Sato, S.; Terashima, Y.; Ochiai, K.; Sasaki, H.; Mizutani, K.; Honjo, H.; Yamamoto, T.; Ozaki, M.; Yamamoto, K.; Hasegawa, K.; Nishimura, R.; Kudo, T.; Kobashi, Y.; Yakushiji, M.; Sugiyama, T.; Hasuo, Y.; Onishi, Y. [Effect of 5'-DFUR used concurrently in radiotherapy and immunotherapy uterine cervical cancer--pilot study. Study of 5'-DFUR for Uterine Cervical Cancer]. Gan to kagaku ryoho. Cancer & Chemotherapy, 1998, 25(5), 705-711.
83. Vetvicka, V.; Vetvickova, J. Combination of glucan, resveratrol and vitamin C demonstrates strong anti-tumor potential. Anticancer Res., 2012, 32(1), 81-87.
84. Lehne, G.; Haneberg, B.; Gaustad, P.; Johansen, P.W.; Preus, H.; Abrahamsen, T.G. Oral administration of a new soluble branched beta-1,3-D-glucan is well tolerated and can lead to increased salivary concentrations of immunoglobulin A in healthy volunteers. Clin. Exp. Immunol., 2006, 143(1), 65-69.
85. Gaullier, J.M.; Sleboda, J.; Ofjord, E.S.; Ulvestad, E.; Nurminiemi, M.; Moe, C.; Tor, A.; Gudmundsen, O. Supplementation with a soluble beta-glucan exported from Shiitake medicinal mushroom, Lentinus edodes (Berk.) singer mycelium: a crossover, placebocontrolled study in healthy elderly. Int. J. Med. Mushrooms, 2011, 13(4), 319-326.
86. Tokuyasu, H.; Takeda, K.; Kawasaki, Y.; Sakaguchi, Y.; Isowa, N.; Shimizu, E.; Ueda, Y. High plasma concentration of beta-D-glucan after administration of sizofiran for cervical cancer. Int. J. Gen. Med., 2010, 3, 273-277.
87. Ebina, T.; Fujimiya, Y. Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice. Biother, 1998, 11(4), 259-265.
88. Zhong, W.; Hansen, R.; Li, B.; Cai, Y.; Salvador, C.; Moore, G.D.; Yan, J. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models. J. Immunother., 2009, 32(7), 703-712.
89. Liu, J.; Gunn, L.; Hansen, R.; Yan, J. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Exp. Mol. Pathol., 2009, 86(3), 208-214.
90. Qi, C.; Cai, Y.; Gunn, L.; Ding, C.; Li, B.; Kloecker, G.; Qian, K.; Vasilakos, J.; Saijo, S.; Iwakura, Y.; Yannelli, J.R.; Yan, J. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived betaglucans. Blood, 2011, 117(25), 6825-6836.
91. Li, B.; Cai, Y.; Qi, C.; Hansen, R.; Ding, C.; Mitchell, T.C.; Yan, J. Orally administered particulate beta-glucan modulates tumorcapturing dendritic cells and improves antitumor T-cell responses in cancer. Clin. Cancer Res., 2010, 16(21), 5153-5164.
92. Sun, L.; Zhao, Y. The biological role of dectin-1 in immune response. Int. Rev. Immunol., 2007, 26(5-6), 349-364.
93. Brown, G.D.; Herre, J.; Williams, D.L.; Willment, J.A.; Marshall, A.S.; Gordon, S. Dectin-1 mediates the biological effects of betaglucans. J. Exp. Med., 2003, 197(9), 1119-1124.
94. Herre, J.; Gordon, S.; Brown, G.D. Dectin-1 and its role in the recognition of beta-glucans by macrophages. Mol. Immunol., 2004, 40(12), 869-876.
95. Taylor, P.R.; Brown, G.D.; Reid, D.M.; Willment, J.A.; Martinez-Pomares, L.; Gordon, S.; Wong, S.Y. The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J. Immunol., 2002, 169(7), 3876-3882.
96. Schorey, J.S.; Lawrence, C. The pattern recognition receptor Dectin-1: from fungi to mycobacteria. Curr. Drug Targets, 2008, 9(2), 123-129.
97. Brown, G.D. Dectin-1: A signalling non-TLR pattern-recognition receptor. Nature Rev. Immunol, 2006, 6(1), 33-43.
98. Gantner, B.N.; Simmons, R.M.; Canavera, S.J.; Akira, S.; Underhill, D.M. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med., 2003, 197(9), 1107-1117.
99. Herre, J.; Marshall, A.S.; Caron, E.; Edwards, A.D.; Williams, D.L.; Schweighoffer, E.; Tybulewicz, V.; Reis e Sousa, C.; Gordon, S.; Brown, G.D. Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages. Blood, 2004, 104(13), 4038-4045.
100. Goodridge, H.S.; Simmons, R.M.; Underhill, D.M. Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J. Immunol., 2007, 178(5), 3107-3115.
101. Gross, O.; Gewies, A.; Finger, K.; Schafer, M.; Sparwasser, T.; Peschel, C.; Forster, I.; Ruland, J. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature, 2006, 442(7103), 651-656.
102. Rogers, N.C.; Slack, E.C.; Edwards, A.D.; Nolte, M.A.; Schulz, O.; Schweighoffer, E.; Williams, D.L.; Gordon, S.; Tybulewicz, V.L.; Brown, G.D.; Reis e Sousa, C. Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity, 2005, 22(4), 507-517.
103. Chan, W.K.; Law, H.K.; Lin, Z.B.; Lau, Y.L.; Chan, G.C. Response of human dendritic cells to different immunomodulatory polysaccharides derived from mushroom and barley. Int. immunol., 2007, 19(7), 891-899.
104. Rice, P.J.; Kelley, J.L.; Kogan, G.; Ensley, H.E.; Kalbfleisch, J.H.; Browder, I.W.; Williams, D.L. Human monocyte scavenger receptors are pattern recognition receptors for (1-->3)-beta-Dglucans. J. Leukoc. Biol., 2002, 72(1), 140-146.
105. Zhang, M.; Chiu, L.C.; Cheung, P.C.; Ooi, V.E. Growth-inhibitory effects of a beta-glucan from the mycelium of Poria cocos on human breast carcinoma MCF-7 cells: Cell-cycle arrest and apoptosis induction. Oncol. Rep., 2006, 15(3), 637-643.
106. Martin, K.R.; Brophy, S.K. Commonly consumed and specialty dietary mushrooms reduce cellular proliferation in MCF-7 human breast cancer cells. Exp. Biol. Med. (Maywood), 2010, 235 (11), 1306-1314.
107. Aleem, E. The mushroom extract schizophyllan reduces cellular proliferation and induces G2/M arrest in MCF-7 human breast cancer cells. Life Sci. J., 2011, 8(4), 777-784.
108. Hsieh, T.C.; Wu, P.; Park, S.; Wu, J.M. Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP). BMC Complement. Altern. Med., 2006, 6, 30.
109. Lee, S.H.; Hwang, H.S.; Yun, J.W. Antitumor activity of water extract of a mushroom, Inonotus obliquus, against HT-29 human colon cancer cells. Phytother. Res., 2009, 23(12), 1784-1789.
110. Youn, M.J.; Kim, J.K.; Park, S.Y.; Kim, Y.; Park, C.; Kim, E.S.; Park, K.I.; So, H.S.; Park, R. Potential anticancer properties of the water extract of Inonotus [corrected] obliquus by induction of apoptosis in melanoma B16-F10 cells. J. Ethnopharmacol., 2009, 121(2), 221-228.
111. Youn, M.J.; Kim, J.K.; Park, S.Y.; Kim, Y.; Kim, S.J.; Lee, J.S.; Chai, K.Y.; Kim, H.J.; Cui, M.X.; So, H.S.; Kim, K.Y.; Park, R. Chaga mushroom (Inonotus obliquus) induces G0/G1 arrest and apoptosis in human hepatoma HepG2 cells. World J. Gastroenterol., 2008, 14(4), 511-517.
112. Zhao, S.; Ye, G.; Fu, G.; Cheng, J.X.; Yang, B.B.; Peng, C. Ganoderma lucidum exerts anti-tumor effects on ovarian cancer cells and enhances their sensitivity to cisplatin. Int. J. Oncol., 2011, 38(5), 1319-1327.
113. Jedinak, A.; Sliva, D. Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway. Int. J. Oncol., 2008, 33(6), 1307-1313.
114. Mansour, A.; Daba, A.; Baddour, N.; El-Saadani, M.; Aleem, E. Schizophyllan inhibits the development of mammary and hepatic carcinomas induced by 7,12 dimethylbenz(alpha)anthracene and decreases cell proliferation: comparison with tamoxifen. J. Cancer Res. Clin. Oncol., 2012, 138(9), 1579-96.
115. Miller, W.R.; O'Neill, J. The importance of local synthesis of estrogen within the breast. Steroids, 1987, 50(4-6), 537-548.
116. Tekmal, R.R.; Ramachandra, N.; Gubba, S.; Durgam, V.R.; Mantione, J.; Toda, K.; Shizuta, Y.; Dillehay, D.L. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res., 1996, 56(14), 3180-3185.
117. Yue, W.; Wang, J.P.; Hamilton, C.J.; Demers, L.M.; Santen, R.J. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res., 1998, 58(5), 927-932.
118. Grube, B.J.; Eng, E.T.; Kao, Y.C.; Kwon, A.; Chen, S. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. J. Nutr., 2001, 131(12), 3288-3293.